#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "he novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
 DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
 DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
 DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
 DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
 DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
# DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
 DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "29844403"}

SET Evidence = "Our previous study demonstrated that MPT0G211
(Fig. 1a) exhibited potent HDAC6 inhibition (IC50 value
= 0.291 nM) and was 1000-fold more selective for
HDAC6 compared with the other HDAC isoforms [11]."
#132157820 - MPT0G211
a(PUBCHEM:132157820) -| p(HGNC:HDAC6)

SET Evidence = "In
addition, MPT0G211 concentration-dependently
increased the acetylation of α-tubulin in SH-SY5Y and
Neuro-2a cells, the common used neuronal cell lines in
the study of AD, at concentrations ranging from 0.1 to 1
μM without affecting the acetylation of histones, which is
consistent with the selective inhibition of HDAC6
(Fig. 1b, c)."
SET CellLine = {"SH-SY5Y","Neuro-2a cell"}
SET MeSHDisease = "Alzheimer Disease"
a(PUBCHEM:132157820) -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
a(PUBCHEM:132157820) cnc p(MESH:Histones,pmod(Ac))
UNSET MeSHDisease
UNSET CellLine

SET Evidence = "In
addition, MPT0G211 treatment did not result in any
significant cytotoxicity in SH-SY5Y and Neuro-2a cells
after 24 h (Fig. 1d), suggesting that the concentrations
used in this study (0.01–1 μM) did not cause cell death."
SET CellLine = {"SH-SY5Y","Neuro-2a cell"}
a(PUBCHEM:132157820) -| path(MESH:"Cytotoxicity, Immunologic")
a(PUBCHEM:132157820) -| bp(GO:"cell death")
UNSET CellLine

SET Evidence = "In addition, Aβ can increase
the accumulation of tau aggregates as well as NFTs,
leading to synaptic dysfunction and eventually neuronal
death [2,7]."
a(CHEBI:"amyloid-beta") -> p(CONSO:"Tau aggregates")
a(CHEBI:"amyloid-beta") -> p(MESH:"Neurofibrillary Tangles")
p(CONSO:"Tau aggregates") -> path(HP:"Abnormal synaptic transmission")
p(MESH:"Neurofibrillary Tangles") -> path(HP:"Abnormal synaptic transmission")
path(HP:"Abnormal synaptic transmission") -> bp(GO:"neuron death")

SET CellLine = {"SH-SY5Y","Neuro-2a cell"}

SET Evidence = "The phosphorylation
of tau Ser396 was significantly increased in the cells
transfected with P301L, and tau was hyperphosphorylated
in cells cotransfected with hAPP 695 in SH-SY5Y and
Neuro-2a cells (Fig. 2c, d)."
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT,pmod(Ph,Ser,396))
p(CONSO:"APP695",var("?")) -> p(HGNC:MAPT,pmod(CONSO:hyperphosphorylation))

SET Evidence = "As reported, MPT0G211 treatment significantly
inhibited the phosphorylation of tau Ser396 in
both cell lines (Fig. 2e, f)."
a(PUBCHEM:132157820) -| p(HGNC:MAPT,pmod(Ph,Ser,396))

SET Evidence = "It is known that hyperphosphorylation also
increases the capacity of tau assembles to form aggregates
from oligomers to fibrils, eventually leading to their
deposition as NFTs and causing neuronal dysfunction,
including reduced mitochondrial respiration, altered
mitochondrial dynamics, and impaired axonal transport [14]."
p(HGNC:MAPT,pmod(CONSO:hyperphosphorylation)) -> p(CONSO:"Tau aggregates")
p(HGNC:MAPT,pmod(CONSO:hyperphosphorylation)) -> p(CONSO:"Tau oligomers")
p(CONSO:"Tau oligomers") -> p(CONSO:"Tau fibrils")
p(HGNC:MAPT,pmod(CONSO:hyperphosphorylation)) -> p(MESH:"Neurofibrillary Tangles")
p(HGNC:MAPT,pmod(CONSO:hyperphosphorylation)) -> path(DOID:neuropathy)
p(HGNC:MAPT,pmod(CONSO:hyperphosphorylation)) neg bp(GO:"cellular respiration")
p(HGNC:MAPT,pmod(CONSO:hyperphosphorylation)) neg bp(GO:"axonal transport")

SET Evidence = "As demonstrated, cytosolic levels of tau
associated with membranes and, in aggregates, were significantly
increased in SH-SY5Y cells cotransfected with
hAPP 695 and hTau P301L (Fig. 3a). Treatment of the
transfectants with MPT0G211 significantly reduced the
levels of aggregated tau (Fig. 3a)."
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT,loc(GO:cytosol))
p(CONSO:"APP695",var("?")) -> p(HGNC:MAPT,loc(GO:cytosol))
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT,loc(CONSO:"Tau aggregates"))
p(CONSO:"APP695",var("?")) -> p(HGNC:MAPT,loc(CONSO:"Tau aggregates"))
a(PUBCHEM:132157820) -| p(HGNC:MAPT,loc(CONSO:"Tau aggregates"))

SET Evidence = "Since Hsp90 is a substrate of HDAC6, the downregulation
of the expression or activity of HDAC6 has been reported
to promote Hsp90 acetylation, thereby favoring tau
degradation [17,18]."
p(HGNC:HDAC6) -- p(HGNCGENEFAMILY:"Heat shock 90kDa proteins")
p(HGNC:HDAC6) -| p(HGNCGENEFAMILY:"Heat shock 90kDa proteins",pmod(Ac))
p(HGNCGENEFAMILY:"Heat shock 90kDa proteins",pmod(Ac)) -> deg(p(HGNC:MAPT))

SET Evidence = "As indicated, plasmid
cotransfection significantly increased HDAC6/Hsp90
binding (Fig. 4a)."
#plasmid - P301L, APP695
p(HGNC:MAPT,var("p.Pro301Leu")) -> complex(p(HGNC:HDAC6),p(HGNCGENEFAMILY:"Heat shock 90kDa proteins"))
p(CONSO:"APP695",var("?")) -> complex(p(HGNC:HDAC6),p(HGNCGENEFAMILY:"Heat shock 90kDa proteins"))

SET Evidence = "In addition, MPT0G211 treatment
clearly enhanced the acetylation of Hsp90, which caused
the downregulation of HDAC6/Hsp90 binding (Fig. 4a)."
a(PUBCHEM:132157820) -> p(HGNCGENEFAMILY:"Heat shock 90kDa proteins",pmod(Ac))
p(HGNCGENEFAMILY:"Heat shock 90kDa proteins",pmod(Ac)) -| complex(p(HGNC:HDAC6),p(HGNCGENEFAMILY:"Heat shock 90kDa proteins"))

SET Evidence = "In cells treated with MPT0G211, coimmunoprecipitation
of ubiquitin with p-tau (Ser396) clearly increased (Fig. 4b),
and the level of polyubiquitinated proteins significantly
accumulated (Fig. 4c)."
a(PUBCHEM:132157820) -> p(HGNC:MAPT,pmod(Ph,Ser,396),pmod(Ub))
p(HGNC:MAPT,pmod(Ph,Ser,396),pmod(Ub)) -> deg(p(HGNC:MAPT))
a(PUBCHEM:132157820) -> deg(p(HGNC:MAPT))

SET Evidence = "In addition, proteasome inhibitor
MG132 treatment significantly reversed the MPT0G211-
induced inhibition of p-tau at Ser396 in both cell lines
(Fig. 4d)."
#462382 - MG132
a(PUBCHEM:462382) -> p(HGNC:MAPT,pmod(Ph,Ser,396))

SET Evidence = "In addition, the activity of GSK3β is
dependent on its phosphorylation at specific sites,
including Ser9 and Tyr216, which can inhibit or increase
GSK3β activity, respectively [19]."
p(HGNC:GSK3B,pmod(Ph,Ser,9)) -- act(p(HGNC:GSK3B))
p(HGNC:GSK3B,pmod(Ph,Tyr,216)) -- act(p(HGNC:GSK3B))

SET Evidence = "As demonstrated, phosphorylation
of tau Ser396 and Ser404 significantly increased in the
cells transfected with the plasmids, but no increases or
mild increases in the phosphorylation of other sites
(Ser262 and Ser356) were observed (Fig. 5a)."
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT,pmod(Ph,Ser,396))
p(CONSO:"APP695",var("?")) -> p(HGNC:MAPT,pmod(Ph,Ser,396))
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT,pmod(Ph,Ser,404))
p(CONSO:"APP695",var("?")) -> p(HGNC:MAPT,pmod(Ph,Ser,404))
p(HGNC:MAPT,var("p.Pro301Leu")) cnc p(HGNC:MAPT,pmod(Ph,Ser,262))
p(CONSO:"APP695",var("?")) cnc p(HGNC:MAPT,pmod(Ph,Ser,262))
p(HGNC:MAPT,var("p.Pro301Leu")) cnc p(HGNC:MAPT,pmod(Ph,Ser,356))
p(CONSO:"APP695",var("?")) cnc p(HGNC:MAPT,pmod(Ph,Ser,356))

SET Evidence   = "MPT0G211
treatment significantly attenuated the phosphorylation of
tau Ser396 and Ser404 in both cell lines (Fig. 5a); no
marked changes in CDK5, p25, or p35 expression were
associated with MPT0G211-induced phospho-tau downregulation;
however, significant phospho-GSK3β increases
on Ser9 through Akt phosphorylation were associated
with the inhibition of phospho-tau Ser396 in response to
MPT0G211 treatment (Fig. 5b).In addition, a decrease in
phospho-GSK3β on Ser216 was also observed."
a(PUBCHEM:132157820) -| p(HGNC:MAPT,pmod(Ph,Ser,396))
a(PUBCHEM:132157820) -| p(HGNC:MAPT,pmod(Ph,Ser,404))
a(PUBCHEM:132157820) cnc p(HGNC:CDK5)
a(PUBCHEM:132157820) cnc p(HGNC:CDK5R1)
a(PUBCHEM:132157820) -> p(FPLX:AKT,pmod(Ph))
p(FPLX:AKT,pmod(Ph)) -> p(HGNC:GSK3B,pmod(Ph,Ser,9))
p(HGNC:GSK3B,pmod(Ph,Ser,9)) -| p(HGNC:MAPT,pmod(Ph,Ser,396))
a(PUBCHEM:132157820) -| p(HGNC:GSK3B,pmod(Ph,Ser,216))

SET Evidence = "As
reported, Aβ 1–40-induced significant p-GSK3β (Ser9)
attenuation and increase in p-tau (Ser396); MPT0G211
treatment diminished GSK3β activity and Aβ 1–40-induced
tau phosphorylation (Fig. 5c)."
a(CHEBI:"amyloid-beta polypeptide 40") -| p(HGNC:GSK3B,pmod(Ph,Ser,9))
a(CHEBI:"amyloid-beta polypeptide 40") -> p(HGNC:MAPT,pmod(Ph,Ser,396))
a(PUBCHEM:132157820) -| act(p(HGNC:GSK3B))
a(PUBCHEM:132157820) -| p(HGNC:MAPT,pmod(Ph,Ser,396))

UNSET CellLine

#cell line used - 3xTg-AD mice with APP(swe) X tau P301L mutants
SET Species = "10090"

SET Evidence = "Oral administration of
MPT0G211 significantly ameliorated memory impairment
(Fig. 6a)."
a(PUBCHEM:132157820) -> bp(GO:memory)

SET Evidence = "Immunohistochemical analysis revealed
that mutant transgenes mediated increases in total tau
and tau phosphorylation at Ser396/Ser404 in the hippocampal
CA1 region of mice that harbor tauP301L mutant
transgene; MPT0G211 treatment significantly downregulated
p-Tau (S396) and p-Tau (S404) expression and
increased acetyl-α-tubulin accumulation in the 3×Tg-AD
mice brain (Fig. 6b).These results provide
strong support that MPT0G211 treatments can ameliorate
Alzheimer’s deficits."
SET MeSHAnatomy = "CA1 Region, Hippocampal"
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT)
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT,pmod(Ph,Ser,396))
p(HGNC:MAPT,var("p.Pro301Leu")) -> p(HGNC:MAPT,pmod(Ph,Ser,396))
a(PUBCHEM:132157820) -| p(HGNC:MAPT,pmod(Ph,Ser,396))
a(PUBCHEM:132157820) -| p(HGNC:MAPT,pmod(Ph,Ser,396))
a(PUBCHEM:132157820) -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
a(PUBCHEM:132157820) -| path(DOID:"Alzheimer's disease")
UNSET MeSHAnatomy

SET Evidence = "These results clearly indicated
that MPT0G211 can penetrate the BBB, where it potentially
ameliorates learning and memory deficits."
a(PUBCHEM:132157820) -> tloc(a(PUBCHEM:132157820),fromLoc(MESH:Blood),toLoc(MESH:Brain))
a(PUBCHEM:132157820) -> bp(GO:learning)
a(PUBCHEM:132157820) -> bp(GO:memory)
